OncoDaily

ROSELLA Trial at ASCO 2026: Relacorilant Improves OS in Ovarian Cancer

The ROSELLA trial brought a new mechanism to the ASCO 2026 stage in one of oncology’s most stubborn settings: platinum-resistant ovarian cancer, where chemotherapy options are limited and survival has changed little in years. Presented by Lucy Gilbert, MD, MSc from McGill University Health Centre, Montreal, the analysis reported final overall survival (OS) results — and asked a question that matters to every patient facing this diagnosis: can adding a glucocorticoid receptor antagonist to chemotherapy help them live longer?

Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist designed to restore tumor sensitivity to chemotherapy-induced cell death. ROSELLA tested whether combining it with weekly nab-paclitaxel could outperform nab-paclitaxel alone — the most active single-agent chemotherapy in this disease — and the trial was designed around the two endpoints that define a meaningful advance: progression-free survival and overall survival.

Read more:
https://oncodaily.com/trial-updates/rosella-trial-asco-2026

25 Posts Not To Miss From ASCO 2026 Day 4

The Day 4 of ASCO 2026 continued the momentum of innovation and collaboration in oncology, with a focus on refining treatment strategies and addressing key challenges in cancer care. Sessions highlighted ongoing research, practical insights, and the integration of new therapies into clinical practice. Discussions emphasized the importance of evidence-based approaches to improve patient outcomes and foster sustainable advancements in the field.

Read here:
https://oncodaily.com/not-to-miss/asco26-513975

Deeply Honored to Receive the Indo-American-Cancer-Association Award at ASCO26 - Vivek Subbiah

https://oncodaily.com/voices/vivek-subbiah-513845

Investing in Healthcare Workers For Cervical Cancer Prevention in Rwanda - Nzobonankira Euloge

https://oncodaily.com/voices/nzobonankira-euloge-513592

The Yvonne Awards Ceremony by OncoDaily Was Truly Oscar-Worthy - Amalya Sargsyan

Red carpet, beautiful dresses, oncologists, researchers, leaders, and of course, the greatest reception.

It was such an honor to co-present the Breakthrough Research Award with a very special person, Dr. Garo Armen, scientist, entrepreneur, philanthropist, global leader, and co-founder and CEO of Agenus.

Read more:
https://oncodaily.com/voices/amalya-sargsyan-513777

Journal Club with Scott – Resonance

We look forward to seeing you every Friday at 9 am ET to enjoy lively discussion of leukemia and supportive care topics.

Date: June 5, 2026
Time: 05:00 PM – 06:00 PM AMT (09:00 AM – 10:00 AM ET)
Presenter: Scott Howard
Organizer: ALRCaN Global/Resonance Health

Yeolyan Hematology and Oncology Center, Ministry of Health of Armenia

Read more:
https://oncodaily.com/voices/resonance-511169

Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26

The Phase III RASolute 302 trial data presented at ASCO 2026 has sparked widespread discussion across digital oncology platforms. Evaluating the multi-selective RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic cancer, the trial earned a rare standing ovation for nearly doubling median overall survival to 13.2 months. Digital discourse is heavily focused on whether these unprecedented results officially shatter the “undruggable” status of the RAS oncogene, with clinicians online actively debating how quickly this breakthrough will reshape the global standard of care.

Read here:
https://oncodaily.com/voices/rasolute-513272

30 Posts Not To Miss From ASCO 2026 Day 3

The Annual Meeting of the American Society of Clinical Oncology (ASCO) is a cornerstone event in oncology, uniting clinicians, researchers, and industry leaders to shape the future of cancer care. On Day 3 of ASCO 2026, the focus shifted to pivotal discussions on cutting-edge treatments, emerging research, and collaborative solutions to advance global oncology. The day highlighted transformative insights that are redefining standards in cancer therapy and patient outcomes.

Read here:
https://oncodaily.com/not-to-miss/asco-not-to-miss-512985